Core Viewpoint - The announcement details the upcoming listing and circulation of restricted shares for Nanjing Mailland Medical Technology Co., Ltd., which will take place on February 11, 2026, involving a total of 63,173,210 shares, representing 63.1732% of the company's total share capital [2][4][24]. Group 1: Listing Details - The type of stock being listed is restricted shares from the initial public offering (IPO), with a total of 63,173,210 shares set for circulation [2][24]. - The shares will be available for trading starting on February 11, 2026 [4][25]. Group 2: Share Capital Changes - Following the IPO, the company's total share capital was established at 100 million shares, with 77,642,626 shares subject to restrictions and 22,357,374 shares unrestricted [4]. - The total share capital increased to 100.62 million shares after the first grant of restricted stock in May 2023, but was later reduced back to 100 million shares due to the termination of the stock incentive plan in April 2024 [5][6]. Group 3: Shareholder Commitments - Shareholders holding restricted shares have made commitments regarding the lock-up period, including not transferring shares for 36 months post-IPO and adhering to specific conditions for any future share sales [8][10][14]. - If the stock price falls below the IPO price for a specified period, the lock-up period will automatically extend by at least six months [8][10][14]. Group 4: Compliance and Verification - The sponsor institution, Nanjing Securities Co., Ltd., has verified that the shareholders have complied with their commitments regarding the restricted shares, confirming that the listing and circulation of these shares meet legal and regulatory requirements [22][23].

证券代码：688273 证券简称：麦澜德 公告编号：2026-002 南京麦澜德医疗科技股份有限公司 关于首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 63,173,210股。 六次会议，审议通过了《关于向激励对象首次授予限制性股票的议案》。公司于 2023 年 5 月 9 日完成了 2023 年限制性股票激励计划第一类限制性股票授予登记工 作，公司总股本由 10,000 万股增加至 10,062 万股。具体内容详见公司于 2023 年 5 月 11 日在上海证券交易所网站（www.sse.com.cn）披露的《2023 年限制性股票激 励计划第一类限制性股票授予结果公告》（公告编号：2023-027）。 本次股票上市流通总数为63,173,210股。 本次股票上市流通日期为2026 年 2 月 11 日。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会出具的《关于同意南京麦澜德医疗科技股份有 限 ...

南京证券股份有限公司 关于南京麦澜德医疗科技股份有限公司 二、本次上市流通的限售股形成后至今公司股本数量变化情况 首次公开发行部分限售股上市流通事项的核查意见 南京证券股份有限公司（以下简称"保荐机构"）作为南京麦澜德医疗科技股 份有限公司（以下简称"麦澜德"或"公司"）首次公开发行股票并上市及持续督导 的保荐机构，根据《中华人民共和国公司法》《中华人民共和国证券法》《上海 证券交易所科创板股票上市规则》等有关规定，对麦澜德首次公开发行部分限售 股上市流通事项进行了核查，发表如下意见： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会出具的《关于同意南京麦澜德医疗科技股份有 限公司首次公开发行股票注册的批复》（证监许可〔2022〕1189 号），南京麦 澜德医疗科技股份有限公司（以下简称"公司"）获准向社会公众公开发行人民币 普通股（A 股）2,500 万股，并于 2022 年 8 月 11 日在上海证券交易所科创板上 市，发行完成后公司总股本为 100,000,000 股，其中有限售条件流通股为 77,642,626 股，无限售条件流通股为 22,357,374 股。 本次上市流通的限售股均为公司首 ...

Quantum Technology - IonQ announced an $1.8 billion acquisition of SkyWater Technology to accelerate its roadmap towards fault-tolerant quantum computing, with plans to start functionality testing of 200,000 qubit QPUs by 2028 [6][8] - A Chinese research team discovered new principles in quantum systems using the 78-qubit superconducting quantum processor "Zhuangzi No. 2," which enhances the application of quantum computing in fields like financial modeling and drug development [7][9] Biomanufacturing - Kangnuo Biopharmaceutical submitted an application for listing on the Hong Kong Stock Exchange, focusing on mitochondrial medicine and NAD+ applications, with projected revenues of 303 million yuan in 2023 [10][11] - Guangdong Province released an action plan aiming for a 40% self-sufficiency rate in core strains of biomanufacturing by 2027, with a total output value exceeding 500 billion yuan [11] Hydrogen Energy and Nuclear Fusion - Sichuan Fusion New Energy Industry Investment Development Co., Ltd. officially commenced operations, supporting the construction of China's first internationally recognized fusion city [13] - CIMC Anrui announced the successful launch of China's first IV-type hydrogen gas bundle container, marking a significant advancement in domestic hydrogen storage and transportation technology [14] - Mingyang Electric and global leaders in hydrogen equipment established Guangdong Mingnuo Hydrogen Technology Co., focusing on high-end hydrogen equipment production [15] Brain-Computer Interface - Neuralink reported 21 participants in its human trials, with plans to enhance device performance by three times and introduce "blindsight" technology for the visually impaired by late 2026 [23][24] - The National Medical Products Administration in China is advancing the establishment of industry standards for brain-computer interface medical devices [28] Embodied Intelligence - Ant Group's Lingbo Technology open-sourced the LingBot-Depth model, significantly lowering development barriers in the industry and enhancing its competitive edge [31][32] 6G and Commercial Aerospace - CASIC successfully conducted a 120 Gbps laser communication experiment, doubling the previous rate and laying the groundwork for high-speed data transmission in commercial aerospace [33][34] - China plans to expand its "Space+" future industries, focusing on space infrastructure, resource development, and space tourism [36] Future Industry Catalysts - Key milestones for future industries in 2026 include significant events in quantum technology, biomanufacturing, hydrogen energy, brain-computer interfaces, embodied intelligence, and 6G [37][38]

Group 1 - The core viewpoint of the news is that 麦澜德 experienced a decline in stock price and has significant financing activities, indicating a high level of market interest and potential volatility [1] - As of January 26, 麦澜德's stock price fell by 3.09%, with a trading volume of 95.12 million yuan, and a net financing purchase of 1.08 million yuan [1] - The total financing and securities balance for 麦澜德 reached 125 million yuan, with a financing balance of 124 million yuan, accounting for 7.41% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of September 30, 麦澜德 had 6,402 shareholders, an increase of 17.23%, while the average circulating shares per person decreased by 14.70% [2] - For the period from January to September 2025, 麦澜德 reported a revenue of 344 million yuan, a year-on-year increase of 4.01%, while the net profit attributable to shareholders was approximately 96 million yuan, a slight decrease of 0.07% [2] - 麦澜德 has distributed a total of 297 million yuan in dividends since its A-share listing, with 247 million yuan distributed over the past three years [3] Group 3 - As of September 30, 2025, among the top ten circulating shareholders of 麦澜德, 华夏稳增混合 (519029) ranked fourth with 701,500 shares, a decrease of 550,500 shares from the previous period [3] - Notably, 中信建投轮换混合A (003822), 中信建投甄选混合A (008347), and 汇添富成长焦点混合 (519068) have exited the list of top ten circulating shareholders [3]

每经AI快讯，有投资者在投资者互动平台提问：请问欧盟地区业务收入在公司整体营业收入中的占比 大致为多少？此外，公司对欧盟市场的销售主要通过哪种方式实现？是以境内主体直接向欧盟客户出口 为主，还是通过在欧盟国家设立的子公司进行销售，或通过第三方贸易商、代理商转销至欧盟市场？ 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前核实。据此操作，风险自担。 麦澜德（688273.SH）1月19日在投资者互动平台表示，目前欧盟地区业务收入较少，未对公司整体营 收构成重大影响，请广大投资者注意投资风险。公司对欧盟市场销售方式主要是通过欧盟境内经销商在 本地销售。 （记者 王晓波） ...

Group 1 - The core point of the news is that 麦澜德 experienced a decline of 5.05% in its stock price, reaching 49.09 yuan per share, with a trading volume of 168 million yuan and a turnover rate of 9.12%, resulting in a total market capitalization of 4.909 billion yuan [1] - 麦澜德 is a company based in Nanjing, Jiangsu Province, established on January 16, 2013, and listed on August 11, 2022. The company specializes in the research, development, production, sales, and services related to pelvic floor and postpartum rehabilitation products [1] - The main revenue composition of 麦澜德 includes pelvic rehabilitation products (36.98%), reproductive rehabilitation products (33.10%), consumables and accessories (24.32%), sports rehabilitation products (2.77%), and other products (2.84%) [1] Group 2 - 金元顺安基金 has a significant holding in 麦澜德, with its 金元顺安成长动力灵活配置混合 fund holding 20,000 shares, accounting for 2.88% of the fund's net value, making it the fifth-largest holding [2] - The fund has a total scale of 28.1676 million yuan, with a year-to-date return of 6.62%, ranking 2154 out of 8840 in its category, and a one-year return of 34.98%, ranking 3623 out of 8094 [2] - The fund manager, 孔祥鹏, has been in position for 8 years and 204 days, with a total asset scale of 143 million yuan, while the other manager, 韩辰尧, has been in position for 2 years and 322 days, managing 873 million yuan [3]

Summary of the Conference Call for MylanDe Company Company Overview - MylanDe Company focuses on brain-computer interface (BCI) products, targeting hospitals with pricing between 500,000 to 1,000,000 yuan at the hospital terminal, with discounts for distributors [2][3] - The company plans to enter 40 to 50 hospitals by 2026, with a sales target of over 10 million yuan in the first year for new products [2][6] Industry Insights - The pricing for BCI devices is approximately 900 yuan per session, with significant support from medical insurance, although specific reimbursement ratios are not yet clear [2][5] - The company is strategically positioned in the non-invasive BCI market, focusing on cognitive, motor rehabilitation, and closed-loop neural regulation [2][12] Core Technology and R&D - MylanDe's core technology is multimodal, integrating EEG and near-infrared technologies, developed in collaboration with Zhejiang University to enhance data accuracy and treatment efficacy [2][10] - The company invests several million yuan annually in R&D, with a commitment of over 100 million yuan for BCI projects, including a partnership with Jiangsu Province BCI Research Institute [4][13] Market Strategy - The company has established a sales team that includes existing rehabilitation and medical business teams, with plans to expand into new channels such as neurology and mental rehabilitation [5][14] - MylanDe aims to maintain a competitive edge with a six-month lead in the market and plans to introduce iterative products to solidify its market position [8][11] Product Development and Future Plans - MylanDe is focused on obtaining regulatory certifications for BCI products in cognitive and motor rehabilitation by 2027, with additional products expected by 2028 [12][20] - The anticipated gross margin for new products is between 75% to 80%, with expectations of significant profit contributions as sales scale up [21] Competitive Landscape - The company has a competitive advantage in the non-invasive BCI sector, with a focus on neural regulation, and is exploring partnerships for further development in the rehabilitation space [8][16] - MylanDe is also considering the potential for semi-invasive or invasive BCI technologies in the future [20] Financial Projections - The company expects growth in its pelvic floor and anti-aging product lines, with projected growth rates of approximately 10% for pelvic floor products and 10%-20% for anti-aging products in 2026 [28] Additional Insights - MylanDe is actively seeking domestic alternatives for imported components to stabilize its supply chain and reduce dependency [18][19] - The company is exploring the consumer market (To C) in the long term, with plans to expand applications beyond medical uses [22] - AI integration in medical applications is a focus area, with ongoing development of personalized treatment plans and a database for BCI data [24]

Macroeconomic Insights - December CPI year-on-year growth expanded, primarily due to a low base and rising food prices[8] - PPI year-on-year decline narrowed, influenced by rising non-ferrous metal prices and the ongoing effects of "anti-involution" policies[8] - The price environment may continue to improve in 2026, with PPI supported by deepening "anti-involution" policies and tightening competition for key minerals[8] Market Trends - In December, the top 100 real estate companies achieved a total sales amount of CNY 341.5 billion, a month-on-month increase of 39.7%[33] - For the full year 2025, the cumulative sales amount for the top 100 real estate companies was CNY 3.36 trillion, a year-on-year decrease of 19.8%[33] - The new stock market saw 18 new listings in December, raising over CNY 30 billion, with average first-day gains of 214% for the main board and 296% for the dual innovation board[18] Industry Performance - The credit bond issuance volume increased seasonally, with a total of 332 bonds issued, amounting to CNY 312.27 billion, a week-on-week increase of 306%[22] - The domestic electrolytic aluminum price reached CNY 23,300 per ton, the highest since March 2022, with the aluminum-to-copper price ratio hitting a 20-year high[42] - The solid-state battery industry is entering a new phase of industrialization, with expectations for mass production by 2026-2027[47]

Group 1 - Institutional investors have shown interest in 41 stocks this week, with 6 stocks receiving target prices [1] - Kelu Electronics received an "Outperform" rating from Guosen Securities, with a target price of 9.70 to 10.10 CNY, while the latest closing price was 8.13 CNY [1] - Lepu Medical was rated "Overweight" by Guojin Securities, with a target price of 21.00 CNY, and the latest closing price was 19.45 CNY [1] Group 2 - Mcland received a "Buy" rating from Everbright Securities, with a target price of 56.65 CNY, and the latest closing price was 53.24 CNY [1] - Other stocks such as China Merchants Bank, Weidao Nano, and Zhongtong Bus also received initial attention from institutions this week [1]